ICICI Prudential Asset Management Co Ltd Purchases 8,529 Shares of Amgen Inc. $AMGN

ICICI Prudential Asset Management Co Ltd increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 35.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 32,267 shares of the medical research company’s stock after purchasing an additional 8,529 shares during the period. Amgen makes up about 1.0% of ICICI Prudential Asset Management Co Ltd’s investment portfolio, making the stock its 23rd largest position. ICICI Prudential Asset Management Co Ltd’s holdings in Amgen were worth $9,106,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the business. Pekin Hardy Strauss Inc. purchased a new stake in shares of Amgen during the 3rd quarter valued at about $204,000. Clear Creek Financial Management LLC increased its stake in Amgen by 19.0% during the third quarter. Clear Creek Financial Management LLC now owns 2,438 shares of the medical research company’s stock worth $688,000 after acquiring an additional 390 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Amgen by 22.5% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 192,706 shares of the medical research company’s stock worth $53,918,000 after acquiring an additional 35,423 shares during the last quarter. Wealth Alliance LLC raised its position in Amgen by 4.6% during the third quarter. Wealth Alliance LLC now owns 13,412 shares of the medical research company’s stock valued at $3,785,000 after purchasing an additional 595 shares during the period. Finally, King Luther Capital Management Corp lifted its stake in shares of Amgen by 0.3% in the 3rd quarter. King Luther Capital Management Corp now owns 509,158 shares of the medical research company’s stock valued at $143,684,000 after purchasing an additional 1,653 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Trading Down 1.1%

AMGN stock opened at $375.50 on Friday. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $385.12. The firm’s 50-day moving average is $342.07 and its 200 day moving average is $315.70. The company has a market capitalization of $202.42 billion, a PE ratio of 26.39, a P/E/G ratio of 3.89 and a beta of 0.46. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is 70.84%.

Analyst Ratings Changes

Several research firms recently weighed in on AMGN. The Goldman Sachs Group increased their price target on Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Friday, December 5th. Cantor Fitzgerald increased their target price on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. BMO Capital Markets lifted their price target on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Finally, Oppenheimer set a $400.00 price target on shares of Amgen and gave the company an “outperform” rating in a report on Thursday, January 29th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $345.16.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.